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Abstract
Background: Antagonists of growth hormone-releasing hormone (GHRH) are being developed for the treatment of 
various human cancers.
Methods: MTT assay was used to test the proliferation of SKOV3 and CaOV3. The splice variant expression of GHRH 
receptors was examined by RT-PCR. The expression of protein in signal pathway was examined by Western blotting. 
siRNA was used to block the effect of EGFR.
Results: In this study, we investigated the effects of a new GHRH antagonist JMR-132, in ovarian cancer cell lines SKOV3 
and CaOV3 expressing splice variant (SV)1 of GHRH receptors. MTT assay showed that JMR-132 had strong 
antiproliferative effects on SKOV3 and CaOV3 cells in both a time-dependent and dose-dependent fashion. JMR-132 
also induced the activation and increased cleaved caspase3 in a time- and dose-dependent manner in both cell lines. 
In addition, JMR-132 treatments decreased significantly the epidermal growth factor receptor (EGFR) level and the 
phosphorylation of Akt (p-Akt), suggesting that JMR-132 inhibits the EGFR-Akt pathway in ovarian cancer cells. More 
importantly, treatment of SKOV3 and CaOV3 cells with 100 nM JMR-132 attenuated proliferation and the antiapoptotic 
effect induced by EGF in both cell lines. After the knockdown of the expression of EGFR by siRNA, the antiproliferative 
effect of JMR-132 was abolished in SKOV3 and CaOV3 cells.
Conclusions: The present study demonstrates that the inhibitory effect of the GHRH antagonist JMR-132 on 
proliferation is due, in part, to an interference with the EGFR-Akt pathway in ovarian cancer cells.
Background
Ovarian cancer is the second most common gynecologic
cancer among women and ranks as the most common
cause of death from gynecologic malignancies in the
western world [1]. Ovarian cancer is difficult to diagnose
at an early stage and most patients are discovered at
advanced stage due to lack of effective early screening
methods [2]. Despite the use of cytoreductive surgery and
systemic chemotherapy, the metastatic disease remains
generally incurable with a 5-year survival rate of around
40% for these patients [1]. Therefore, it is critical to intro-
duce more effective therapeutic agents for the manage-
ment of this malignancy.
Antagonists of growth hormone-releasing hormone
(GHRH) are being developed for the treatment of various
cancers [3,4]. Since 1994, many antagonistic analogs of
GHRH have been synthesized in the laboratories of one
of us [3]. GHRH antagonists were shown to inhibit the
proliferation both in vivo and in vitro of various human
cancers, including pancreatic [5], colorectal [6], prostatic
[7-10], breast [11,12], renal [13], glioblastomas [14], oste-
osarcomas and Ewing sarcomas [15,16], lung carcinomas
[17,18], lymphomas [19], as well as ovarian [20] and
endometrial cancer [21]. GHRH antagonists can suppress
tumor growth by indirect and direct pathways. The indi-
rect action is mediated through the suppression of pro-
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duction of the pituitary GH and hepatic insulin-like
growth factor I (IGF-I), which results in growth inhibi-
tion of some tumors [3,22,23]. However, much evidence
from both in vivo and in vitro experiments shows that
GHRH antagonists can also directly suppress tumor cells
growth. Thus, the growth of various human cancers was
suppressed without any involvement of the hypothalamic
GHRH/pituitary GH/hepatic IGF-I axis [3]. The effect
occurs through the disruption of the autocrine/paracrine
production of IGF-I and/or IGF-II in tumors [3,24-26] by
GHRH antagonists, or through the blockade of the stimu-
latory loop formed by tumoral GHRH and its receptors in
tumors [3,27-34].
F o u r  s p l i c e  v a r i a n t s  ( S V s )  o f  G H R H  r e c e p t o r s
(GHRHR) have been demonstrated in various human
cancers and cancer cell lines [3,27]. One of the four iso-
forms, SV1 has the greatest structural similarity to the
pituitary GHRHR and is probably the main SV that medi-
ates the effects of GHRH and its antagonists in tumors
[3,27-34].
JMR-132 is a novel, highly potent GHRH antagonist.
JMR-132 has been shown to inhibit human breast cancer
[35,36], prostate cancer [37] and lung cancer [38,39], but
the effect on ovarian cancer cells has not been reported
so far. Knowledge about the mechanisms of GHRH
antagonists involved in the antiproliferative effects,
including apoptosis and cell circle arrest, is limited. Some
recent studies have shown that cAMP [40], PKC [41], p21
[39] and p53 [42,43] may participate in mediating the
effect of GHRH antagonists on inhibition of proliferation
and the induction of apoptosis.
It has been also proposed that EGFR plays an important
role in ovarian cancer, since this receptor is overex-
pressed in nearly 75% of primary ovarian cancers [44].
The over-expression of EGFR might be related to
advanced-stage disease and poor prognosis [45]. EGFR
regulates essential cellular functions, including prolifera-
tion, apoptosis, migration, and differentiation. Various
ligands, such as EGF, amphiregulin (AR) and transform-
ing growth factor-α (TGFα), are known to bind to EGFR,
and will stimulate receptor homodimerization or het-
erodimerization for initiation of signal transduction. Pub-
l i s h e d  d a t a  d e m o n s t r a t e s  t h a t  t h e  e f f e c t s  o f  E G F R
signaling on cell proliferation and survival are mediated
by PI3K-Akt pathways. Activation of EGFR results in the
activation of the lipid kinase, PI3K, generating the second
messenger phosphatidylinositol 3,4,5-trisphos-
phate(PIP3), which in turn activates Akt [46]. Thus,
EGFR signaling has become an important target in anti-
cancer drug development due to its ability to suppress
apoptosis and to control tumor cell proliferation and
migration [47,48]. Previous in vivo studies in lung cancer
showed that decreased EGFR level might be involved in
the antiproliferative effect of GHRH antagonists [49,50],
but it hasn't been reported in ovarian cancer cell lines by
JMR-132 treatment.
In this study, we for the first time demonstrate that the
antiproliferative effect of JMR-132 in SKOV3 and CaOV3
cells occurs through EGFR pathway-dependent down-
regulation of the p-Akt level, and consequently leads to
the induction of cleaved caspase3, which indicate that
SKOV3 and CaOV3 cells have experienced apoptosis.
Our work also suggests that JMR-132 could be useful in
the treatment of ovarian cancers.
Methods
Reagents
The GHRH antagonist JMR-132 was synthesized in the
laboratories of one of us. Its structure is [PhAc0-Tyr1, D-
Arg2, Phe(4-Cl)6, Ala8, Har9, Tyr(Me)10, His11, Abu15,
His20, Nle27, D-Arg28, Har29] hGH-RH(1-29)NH2, where
Abu is α-aminobutyric acid, Har is homoarginine, Nle is
norleucine, PhAc is phenylacetyl and Tyr(Me) is o-meth-
yltyrosine, as reported previously [3]. The PI3K inhibitor
LY294002 and EGF were purchased from Sigma (St.
Louis, MO, USA).
Cell culture
Human epithelial ovarian cancer cell lines SKOV3 and
CaOV3 classified as adenocarcinomas were obtained
from the American Type Culture Collection (ATCC,
Moanassas, USA). The cells were cultured in Dulbecco's
minimum essential medium (DMEM) (Invitrogen Inc.,
Burlington, ON, Canada) supplemented with 10% fetal
bovine serum (FBS) (HyClone Laboratories Inc., Logan,
UT), 100 U/ml penicillin and 100 mg/ml streptomycin
(Life Technologies, Inc., Rockville, MD, USA) and incu-
bated at 37°C in a humidified incubator with 5% CO2. The
cells were grown to 80% confluence and incubated with
serum free medium overnight before treatment with
JMR-132, EGF and PI3K inhibitor LY294002.
MTT assay
Cell viability was estimated by the [3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazoliumbromide] (MTT)
(Sigma-Aldrich Corp.) assay. CaOV3 or SKOV3 cells
were seeded into 96-well dishes (SKOV3, 2 × 103 cells/
well; CaOV3, 3 × 103 cells/well) with DMEM containing
10% FBS. DMEM medium (180 ul) was added to each
well. After 24 hours of incubation, the cells were treated
with GHRH antagonist JMR-132 (100 nM), EGF (10 ng/
ml) and PI3K inhibitor LY294002 (10 μM). The MTT col-
orimetric assay was performed to detect tumor cell viabil-
ity after 24 h, 48 h, 72 h and 96 h of incubation. The cells
were then incubated at 37°C with 20 μl of MTT solution
(5 mg/ml in PBS) for 4 h. The supernatants were removedGuo et al. Reproductive Biology and Endocrinology 2010, 8:54
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and the cells were solubilized in DMSO (200 μl) for 15
min. The OD at 490 nm was determined using an ELISA
reader (Fisher Scientific Ltd., Ottawa, Canada).
mRNA isolation and RT-PCR
After treatment with JMR-132, the medium was removed
from each culture dish and RNA was extracted using Tri-
zol (Invitrogen). Total RNA (2 μg) was reverse-tran-
scribed into first-strand cDNA (GEHealthcare Bio-
Science, Piscataway NJ, USA) following the manufac-
turer's protocol. The primer for the analysis of mRNA
expression of GHRH receptor SV1 has been described
[28,29]. The primers used were 5'-CCT ACT GCC CTT
AGG ATG CTG G-3' (sense) and 5'-GCA GTA GAG
GAT GGC AAC AAT G-3' (antisense). The PCR condi-
tions were 1 cycle at 95°C for 3 min, followed by 40 cycles
at 95°C for 30 s, 60°C for 30 s and 72°C for 60 s. Four
microliters of the PCR product were then used to per-
form a second PCR. The primers used were 5'-GCA CCT
TTG AAG CCA GAG AAG G-3' (sense) and 5'-CAC
GTG CCA GTG AAG AGC ACG G-3' (antisense). The
product length was 720 bp. The primers for human
GAPDH were 5'-ATGTTCGTCATGGGTGTGAACCA-
3' (sense) and 5'-TGGCAGGTTTTTCTAGACGGCAG-
3' (antisense). The cycling conditions were 94°C for 5 m,
followed by 25 cycles of 94°C for 30 s, 55°C for 30 s and
72°C for 60 s. The product length was 373 bp. The PCR
products were electrophoresed on a 2% agarose gel,
stained with ethidium bromide and visualized under
ultraviolet light.
Western blotting
The cells were homogenized in RIPA lysis buffer contain-
ing 50 nM Tris-HCl pH 7.4, 150 mM NaCl, 1% Nonidet
P-40 and 0.1% SDS, supplemented with protease inhibi-
tors (PMSF) and phosphatase inhibitors (1 mM NaF).
After centrifugation (12000 × g, 15 min), the superna-
tants were collected and the protein concentrations were
determined by spectrophotometer. After boiling at 98°C
for 5 min, 50 μg of total protein per lane was added. The
proteins were separated by 8-10% SDS-PAGE and trans-
ferred to a nitrocellulose membrane. The nitrocellulose
sheet was incubated in 5% nonfat milk for 1 h at room
temperature and then exposed to the primary antibodies
against caspase3, p-Akt, Akt, EGFR and β-actin (1:1000)
at 4°C overnight. After three washes in TBS, the mem-
branes were incubated with the correct peroxidase-con-
jugated secondary antibodies for 1 h at room temperature
and washed again with TBS. The bands were visualized
with Supersignal West Pico Chemiluminescent Substrate
(Pierce Co., USA).
In vitro transfection with small interfering RNAs (siRNAs)
siRNAs targeting EGFR were synthesized by Invitrogen
(Burlington, ON, Canada). In addition, a nonspecific
scrambled siRNA was purchased from Invitrogen and
used as a control. The siRNA transfection was performed
according to the manufacturer's instructions (Invitrogen).
Briefly, 24 hours before transfection, 6-well plates were
seeded with 1 × 104 cells per well in 2 ml of culture
medium. The cells were transfected with EGFR (100 nM
final concentration) or scrambled siRNA with 1 ml of
lipofectamine iMAX reagent according to the manufac-
turer's protocol. 48 hours later, the cells were treated with
JMR-132. For the MTT assay, the cells from the 6-well
plate were re-seeded in a 96-well plate 48 hours after
transfection.
Statistical analysis
Data were subjected to one-way ANOVA and differences
were determined by Tukey's multiple comparison test.
Each experiment was repeated three times. Data are
shown as the means of three individual experiments and
presented as the mean ± SEM. P < 0.0 5 was considered
statistically significant.
Results
The expression of mRNA for GHRHR SV1 in SKOV3 and 
CaOV3 cells
Previous studies showed that GHRHR SV1 was expressed
in different cancer cells. As shown in Figure 1, mRNA for
GHRHR SV1 was expressed in both SKOV3 and CaOV3
cancer cells. LNCaP cells are androgen-sensitive human
prostate adenocarcinoma cells. It has been reported that
splice variants 1(SV1) of GHRH receptors was expressed
in LNCaP cells [27-29]. However, the level of GHRHR
SV1 mRNA in SKOV3 and CaOV3 cells is lower than that
in LNCaP prostate cancer cells, which were used as a pos-
itive control.
The antiproliferative effect of JMR-132 on the SKOV3 and 
CaOV3 cell lines
The growth of the SKOV3 and CaOV3 cells was checked
by the MTT assay. As shown in Figure 2A and 2B, both
the treatment with a different dose per day of JMR-132
Figure 1 The expression of mRNA for GHRHR SV1 in SKOV3 and 
CaOV3 human ovarian cancer cells. The prostate cancer cell line LN-
CaP was used as a positive control. Human GAPDH was used as an in-
ternal control.Guo et al. Reproductive Biology and Endocrinology 2010, 8:54
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Figure 2 Antiproliferative effect of JMR-132 on SKOV3 and CAOV3 cells. SKOV3 (2000/well) and CaOV3 (3000/well) were treated with JMR-132 
at a different dose (25, 50, 100 and 200 nM) per day for 2 days (A), (C) and with 100 nM JMR-132 per day for different periods of time (24, 48, 72 and 96 
h) (B) (D). MTT assay showed that proliferation was inhibited in a dose (A) and time (B) dependent manner after JMR-132 treatment. * P < 0.05 com-
pared to the no treatment group. The expression of cleaved caspase3 increased in a dose (C) and time (D) dependent manner. The results indicated 
that JMR-132 treatment induced apoptosis in these cells.Guo et al. Reproductive Biology and Endocrinology 2010, 8:54
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for 2 days and treatment with 100 nM JMR-132 per day
for 1 to 4 days resulted in a significant decrease in the
growth of SKOV3 and CaOV3 cells compared to the con-
trol group. However, the effect in SKOV3 cells was stron-
ger than that in CaOV3 cells. The maximum inhibition
occurred after continuous treatment for 4 days with 100
nM JMR-132 and reached about 60% in SKOV3 cells.
These data showed that JMR-132 can suppress growth of
SKOV3 and CaOV3 cells in a dose- and time-dependent
manner.
To further clarify whether the antiproliferative effect is
due to growth inhibition or apoptosis induced in the
SKOV3 and CaOV3 cells, we checked the expression of
cleaved caspase3 which is a known marker of apoptosis.
As shown in Figure 2C and 2D, after treatment with JMR-
132, the level of cleaved caspase3 obviously increased in
time- and dose-dependent manner. As seen from growth
inhibition in SKOV3 and CaOV3 cells, the increase in the
level of cleaved caspase3 in SKOV3 cells was greater than
that in CaOV3 cells. Thus apoptosis might contribute to
the antiproliferative effect induced by JMR-132 treatment
in SKOV3 and CaOV3 cells.
Decrease in EGFR level after JMR-132 treatment in SKOV3 
and CaOV3 cells
EGFR plays an important role in proliferation in cancer
research. To determine whether the mechanism of the
antiproliferative effect of JMR-132 is associated with
EGFR, we studied the EGFR protein expression. As
shown in Figure 3, EGFR levels decreased significantly in
SKOV3 and CaOV3 cells after 48 to 96 hours of treat-
ment with 100 nM JMR-132. Our data indicated therefore
t h a t  E G F R  m i g h t  b e  i n v o l v e d  i n  t h e  r e g u l a t i o n  o f  t h e
effect of JMR-132.
JMR-132 attenuates the effect of EGF-induced p-Akt 
activation
To characterize whether the antiproliferative effect is
related to the decreased level of EGFR, we measured
EGFR downstream signaling by Western blotting of Akt
and apoptotic-associated caspase3. We first confirmed
that EGF (10 ng/μl) induced p-Akt activation (Figure 4A).
The treatment of SKOV3 and CaOV3 cells with JMR-132
led to a decrease in p-Akt (Figure 4B), which suggested
that the antiproliferative effect might result from the
PI3K-Akt pathway. Using the PI3K-specific inhibitor
LY294002 as a positive control, we treated the cells with
JMR-132 alone or in combination with EGF and found
that JMR-132 still inhibited p-Akt expression as com-
pared to the control group. In addition, JMR-132 attenu-
ated the EGF-induced increase in the p-Akt level. Our
results indicate that the EGFR-Akt pathway plays a role in
regulating the function of the GHRH antagonist JMR-
132.
JMR-132 abolishes the pro-proliferative and anti-apoptotic 
effect of EGF
To continue the investigation of the EGFR-Akt pathway,
we examined the proliferation of SKOV3 and CaOV3
cells after treatment with JMR-132 alone or in combina-
tion with EGF. As shown in Figure 5A, the growth of
SKOV3 and CaOV3 cells was significantly inhibited after
treatment with JMR-132 alone or in combination with
EGF. The antiproliferative effect was stronger in SKOV3
cells than in CaOV3 cells. We also examined the expres-
sion of caspase3 in SKOV3 and CaOV3 cells after the
same treatment. Similar to the proliferation data, JMR-
132 upregulated the level of cleaved caspase3, which sug-
gested that apoptosis occurred. However, EGFR plays an
antiapoptotic role and no cleaved caspase3 was induced
in the EGF treatment group. Interestingly, treatment with
JMR-132 in combination with EGF again led to an
increase in the level of the cleaved caspase3. The apopto-
sis data are consistent with the proliferation data, sug-
gesting that the antiproliferative effect is mainly due to
the cells undergoing apoptosis and partially to the anti-
proliferative effect of JMR-132 acting on the EGFR-Akt
pathway.
Lack of effect of treatment with JMR-132 after EGFR siRNA 
transfection in SKOV3 and CaOV3 cells
To further confirm that EGFR is involved in mediating
the function of JMR-132, we knocked down EGFR using
100 nM EGFR siRNA. After transfection with 100 nM
EGFR siRNA for 2 days, the EGFR expression was signifi-
cantly decreased. Since we reseeded the cells in a 96-well
plate after stable EGFR siRNA transfection to examine
the cell proliferation with or without JMR-132 treatment
for 2 and 4 days, we checked the long-term expression of
EGFR, which was still low (Figure 6A). In the MTT assay
(Figure 6B), we found that the growth of SKOV3 and
CaOV3 cells was inhibited after EGFR was knocked
down, which indicated that EGFR plays a major role in
cell proliferation. More importantly, no changes in prolif-
Figure 3 The expression of EGFR in SKOV3 and CaOV3 cells de-
creased after JMR-132 treatment. The protein level of EGFR de-
creased after treatment with 100 nM JMR-132 per day for 2 and 4 days. 
β-actin was used as an internal control. The data are from one experi-
ment and are representative of the three separate experiments.Guo et al. Reproductive Biology and Endocrinology 2010, 8:54
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eration were detected after transfection with EGFR
siRNA, following JMR-132 treatment. However, there
was still an inhibitory effect of JMR-132 in the control
siRNA transfection group. The same results were found
for cleaved caspase3 expression in SKOV3 cells (Figure
6C). These data suggest that the antiproliferative effect of
JMR-132 was reduced. Consistent with the results for
proliferation, the level of cleaved caspase3 was slightly
increased after knocking down EGFR, which indicates
that a decrease in the EGFR level results in apoptosis. We
then examined the expression of cleaved caspase3 with or
without JMR-132 treatment after knocking down EGFR,
and no obvious changes between the two groups were
found. These data confirmed that the antiproliferative
effect of JMR-132 is partially due to the decrease in
EGFR. In addition, the effects on growth inhibition and
apoptosis induction after JMR-132 treatment were
greater in the EGFR siRNA group compared to the con-
trol siRNA group, which confirmed the importance of
EGFR in cell proliferation.
Figure 4 JMR-132 attenuated the effect of EGF-induced p-Akt activation. A. p-Akt was activated after EGF (10 ng/ul) treatment without changes 
in Akt. β-actin was used as an internal control. B. p-Akt expression decreased after treatment with 100 nM JMR-132 per day for 2 and 4 days without 
changes in Akt level. C. JMR-132 attenuated the effect of EGF-induced p-Akt expression. JMR-132 (100 nM) and PI3K specific inhibitor LY294002 (10 
nM) were used separately to continuously treat SKOV3 and CaOV3 cells for 2 days. PI3K specific inhibitor LY294002 was used as a positive control. β-
actin was used as an internal control. EGF was added 15 min prior to harvesting.Guo et al. Reproductive Biology and Endocrinology 2010, 8:54
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Discussion
Since 1994, various GHRH analogs with different struc-
tural features, including GHRH agonists and antagonists,
have been synthesized [3]. Many studies were performed
on the effects of the GHRH antagonists on different
experimental cancers or human cancer cell lines. It was
found that the treatment with the GHRH antagonists
inhibit the growth of many human cancers, including
ovarian cancer cell lines [3,20]. Although these observa-
tions have demonstrated the inhibitory role of GHRH
antagonists on the proliferation of ovarian cancer [3,20],
the effects of GHRH antagonists on other aspects of can-
cer phenomena, such as apoptosis, is poorly understood.
It has been also shown that the GHRH antagonist JMR-
132 had antiproliferative effects in lung, breast and pros-
tate cancers [35-39], but the effect of JMR-132 on ovarian
cancer cell lines was not reported. Thus, we conducted
the present study to examine the effect of JMR-132 on
two ovarian cancer cell lines, SKOV3 and CaOV3, and to
investigate the mechanisms involved.
Figure 5 JMR-132 abolished the pro-proliferative and anti-apoptotic effect of EGF. A. Using the MTT assay, it was determined that the growth 
of SKOV3 and CaOV3 cells was significantly inhibited after continuous treatment with 100 nM JMR-132 for 2 days in combination with EGF (10 μg/ml). 
Letters (a, b, c) between pairs indicate significant differences (P < 0.05). B. The expression of cleaved caspase3 increased during treatment with 100 
nM JMR-132 per day for 2 days in combination with EGF (10 μg/ml). β-actin was used as an internal control. EGF was added 15 min prior to harvesting 
in (A) and (B).Guo et al. Reproductive Biology and Endocrinology 2010, 8:54
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Previous studies showed that SV1 of GHRHR expressed
in several cancers, may mediate the direct inhibitory
effect of GHRH antagonists [3,27-34]. Here, we examined
the expression of GHRHR SV1 in SKOV3 and CaOV3
cancer cell lines. Our data are in agreement with previous
studies, indicating that GHRHR SV1 may play a func-
tional role in regulating the effect of GHRH antagonists.
The presence and the role of pituitary type of GHRH
receptor [3,17] in ovarian cancer lines was not investi-
gated in this study.
The effect of the GHRH antagonist JMR-132 on ovarian
cancer cells was primarily studied with the MTT assay.
Treatment with JMR-132 significantly inhibited the pro-
liferation of SKOV3 and CaOV3 ovarian cancer cell lines.
We then considered whether this antiproliferative effect
was due to growth inhibition or apoptosis induction.
Cleaved caspase3, the large fragment (17-19 kDa) of acti-
vated caspase3, results from pro-caspase3 (37KD) and is
a known marker of apoptosis. It was observed that JMR-
132 induced an increase in activated caspase3 in a time-
and dose-dependent manner, which indicates that the
cells were undergoing apoptosis. Both cell cycle arrest
and apoptosis lead to growth inhibition. We also looked
for changes in the cell cycle phase using flow cytometry;
the G1 phase showed no obviously increase (data not
shown). Results from this study demonstrate that growth
suppression induced by JMR-132 treatment may be due
to promoting apoptosis, not by cell cycle arrest. In short,
JMR-132 could activate and increase cleaved caspase3
expression in ovarian cancer cells, which resulted in
apoptosis, thus inhibiting the cell proliferation. There-
fore, the apoptosis induced by JMR-132 treatment was a
main contributor to proliferative inhibition.
The overexpression of EGFR results in an increased
proliferation of solid tumors, including ovarian cancer
[45]. Moreover, EGFR expression correlates with tumor
resistance to chemotherapy [45] and indicates a poor
prognosis. Previous studies suggested that the antiprolif-
Figure 6 No changes were detected after transfection with EGFR siRNA, either with or without JMR-132 treatment. A. EGFR was knocked 
down after transfection with EGFR siRNA for various periods of time. After transfection with 100 nM EGFR siRNA for 48 hours, we reseeded the cells for 
the MTT assay. Pretreatment: after cell reseeding; 48 and 96 hours: treatment with 100 nM JMR-132 per day for 2 and 4 days after cell reseeding. The 
EGFR expression was still lower when compared to the cells transfected with 100 nM control siRNA. B. No changes were found by the MTT assay after 
transfection with EGFR siRNA, with or without JMR-132 treatment. The cells (SKOV3 and CaOV3: 4000/well) were reseeded in a 96-well plate after trans-
fection with control siRNA or EGFR siRNA for 2 days. After 2 and 4 days of treatment with 100 nM JMR-132, the MTT assay was performed. Letters (a, b, 
c) indicate significant differences (P < 0.05) between pairs. C. No changes were detected in cleaved caspase3 expression after transfection with EGFR 
siRNA, either with or without JMR-132 treatment in SKOV3 cells. After transfection with 100 nM EGFR siRNA for 48 hours, the SKOV3 cells were treated 
with 100 nM JMR-132 per day for 2 days. β-actin was used as an internal control.Guo et al. Reproductive Biology and Endocrinology 2010, 8:54
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erative effect of the GHRH antagonist might involve
EGFR [49,50]. However, the molecular mechanisms link-
ing GHRH antagonists to the EGFR pathway in ovarian
cancer cells were not well established. Our findings
showed that the protein level of EGFR decreased after
JMR-132 treatment, which means that the antiprolifera-
tive effect of JMR-132 might be associated with EGFR. It
is well known that the activation of EGFR leads to the
activation of PI3K, which in turn activates Akt, the main
downstream target, which appears to play various impor-
tant roles in regulating cellular growth and apoptosis
[48]. Therefore, to characterize the cell growth inhibition
due to the decrease in EGFR protein, we measured EGFR
downstream signaling of the Akt pathway by Western
blotting. In accord with the decrease in EGFR level, treat-
ment with JMR-132 induced a down-regulation of phos-
phorylation of Akt. More importantly, JMR-132 could
attenuate the EGF-induced, upregulated p-Akt level. It
was also observed that, treatment of SKOV3 and CaOV3
cells with JMR-132 alone, as well as co-treatment with
EGF or treatment with LY294002, a PI3K/Akt inhibitor,
the pro-proliferative effect of EGF was all abolished by
JMR-132. These results demonstrate that the down-regu-
lation of the EGFR-Akt pathway which was induced by
JMR-132 treatment results in inhibition of cell prolifera-
tion. In addition, it was reported that Akt can directly
inhibit caspase9 and caspase3 to avoid apoptosis and
cleaved caspase3 level was activated and increased by
decreased p-Akt level [51]. Then we examined the effect
of EGFR-Akt pathway in apoptotic process. Similar
results were seen with cleaved caspase3 level. The expres-
sion of cleaved caspase3 was still increased after treat-
ment with JMR-132 in combination with EGF. JMR-132
and EGF co-treatment were able to counter the EGF pro-
t e c t i o n  o f  c e l l s ,  w h i c h  l e d  t o  a n  i n c r e a s e  i n  c l e a v e d
caspase3, suggesting that apoptosis still occurred. The
data demonstrate that down-regulation of the EGFR-Akt
pathway induced by JMR-132 treatment is the main con-
tributor in suppression of cell proliferation and induction
of apoptosis.
These observations prompted us to investigate whether
the antiproliferative effect of JMR-132 could be altered if
endogenous EGFR was eliminated. The results confirmed
our hypothesis as there was no difference between the
siControl and siEGFR groups after treatment with JMR-
132. The same findings were observed for cleaved
caspase3 expression. These data suggest that the antipro-
liferative effect of JMR-132 is abolished if EGFR expres-
sion is knocked down, confirming that the
antiproliferative effect of JMR-132 is due to the reduction
in EGFR. Thus, our findings indicate that the effect of
JMR-132 on proliferation may partially be mediated
through the EGFR pathway.
Of much interest was the observation of slowed growth
and cleaved caspase 3 induction in SKOV3 and CaOV3
cells after EGFR knock-down, which indicates that a
decreased level of EGFR results in apoptosis and
decreased proliferation. Furthermore, the effects of JMR-
132 growth inhibition in CaOV3 cells were higher in the
EGFR siRNA group when compared to the control siRNA
group after JMR-132 treatment. All these results point to
the critical role of EGFR in cell proliferation. Therefore,
the inhibition of EGFR level by JMR-132 could be of sig-
nificance in clinical treatment ovarian cancer.
Conclusions
In summary, we show here for the first time that the
GHRH antagonist JMR-132 acts as an effective anti-pro-
liferation agent in the ovarian cancer cell lines, SKOV3
and CaOV3, by inducing apoptosis. Furthermore, we also
shed light on the potential molecular mechanism of JMR-
132, which may occur through partial suppression of the
EGFR-Akt pathway.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JG designed the study and performed the experiments and participated in dis-
cussion of the results and drafted the manuscript. AVS, MZ and JV provided the
reagent of JMR-132, and were responsible for supervision of this work. PCKL
was responsible for the conception, design, discussion of the results, drafting
and critical revision of the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by the Canadian Institutes of Health Research (PCKL), 
and in part by the Medical Research Service of the Veterans Affairs Department 
and the University of Miami Miller School of Medicine Departments of Pathol-
ogy and Medicine Division of Hematology/Oncology (AVS).
Author Details
1Department of Obstetrics & Gynaecology, Child and Family Research Institute, 
UBC, Vancouver, Canada, 2School of Preclinical Medicine, Beijing University of 
Chinese Medicine, Beijing, China and 3Veterans Affairs Medical Center and 
Departments of Pathology and Medicine, Division of Hematology/Oncology, 
University of Miami Miller School of Medicine, Miami, FL 33125, USA
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009.  
CA Cancer J Clin 2009, 59:225-249.
2. Partridge EE, Barnes MN: Epithelial ovarian cancer: prevention, 
diagnosis, and treatment.  CA Cancer J Clin 1999, 49:297-320.
3. Schally AV, Varga JL, Engel JB: Antagonists of growth-hormone-releasing 
hormone: an emerging new therapy for cancer.  Nat Clin Pract 
Endocrinol Metab 2008, 4:33-43.
4. Gelato M: Growth hormone releasing hormone: clinical perspectives 
revisited.  Endocrinologist 2005, 15:159-164.
5. Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G: 
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in 
vivo proliferation of experimental pancreatic cancers and decrease 
IGF-II levels in tumours.  Eur J Cancer 2000, 36:128-136.
6. Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Herbert F, Szende 
B, Varga JL, Zarandi M: Antagonists of growth hormone-releasing 
Received: 2 February 2010 Accepted: 28 May 2010 
Published: 28 May 2010
This article is available from: http://www.rbej.com/content/8/1/54 © 2010 Guo et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Reproductive Biology and Endocrinology 2010, 8:54Guo et al. Reproductive Biology and Endocrinology 2010, 8:54
http://www.rbej.com/content/8/1/54
Page 10 of 11
hormone (GH-RH) inhibit IGF-II production and growth of HT-29 
human colon cancers.  Br J Cancer 2000, 82:1724-1731.
7. Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Armatis P, Vadillo-
Buenfil M: Inhibition of in vivo proliferation of androgen-independent 
prostate cancers by an antagonist of growth hormone-releasing 
hormone.  Br J Cancer 1997, 75:1585-1592.
8. Lamharzi N, Schally AV, Koppan M, Groot K: Growth hormone-releasing 
hormone antagonist MZ-5-156 inhibits growth of DU-145 human 
androgen-independent prostate carcinoma in nude mice and 
suppresses the levels and mRNA expression of insulin-like growth 
factor II in tumors.  Proc Natl Acad Sci USA 1998, 95:8864-8868.
9. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL: Growth hormone-
releasing hormone (GHRH) antagonists inhibit the proliferation of 
androgen-dependent and -independent prostate cancers.  Proc Natl 
Acad Sci USA 2003, 100:1250-1255.
10. Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, 
Halmos G: Inhibitory effect of antagonists of bombesin and growth 
hormone-releasing hormone on orthotopic and intraosseous growth 
and invasiveness of PC-3 human prostate cancer in nude mice.  Clin 
Cancer Res 2005, 11:49-57.
11. Kahan Z, Varga JL, Schally AV, Rekasi Z, Armatis P, Chatzistamou L, 
Czompoly T, Halmos G: Antagonists of growth hormone-releasing 
hormone arrest the growth of MDA-MB-468 estrogen-independent 
human breast cancers in nude mice Breast.  Cancer Res Treat 2000, 
60:71-79.
12. Chatzistamou I, Schally AV, Varga JL, Groot K, Busto R, Armatis P, Halmos G: 
Inhibition of growth and metastases of MDA-MB-435 human estrogen-
independent breast cancers by an antagonist of growth hormone-
releasing hormone.  Anticancer Drugs 2001, 12:761-768.
13. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G: Growth 
hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo 
proliferation of Caki-I renal adenocarcinoma.  Proc Natl Acad Sci USA 
1997, 94:5810-5813.
14. Kiaris H, Schally AV, Varga JL: Antagonists of growth hormone-releasing 
hormone inhibit the growth of U-87MG human glioblastoma in nude 
mice.  Neoplasia 2000, 2:242-250.
15. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M, Armatis P: 
Inhibition of growth of human osteosarcomas by antagonists of 
growth hormone-releasing hormone.  J Natl Cancer Inst 1995, 
87:1787-1794.
16. Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, Armatis 
P: Inhibition of proliferation in human MNNG/HOS osteosarcoma and 
SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of 
growth hormone-releasing hormone: effects on insulin-like growth 
factor II.  Cancer 2002, 95:1735-1745.
17. Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, Köster F, Heinrich 
E, Halmos G, Rick FG, Kannadka C, Datz C, Kanashiro CA: Synergistic 
inhibition of growth of lung carcinomas by antagonists of growth 
hormone-releasing hormone in combination with docetaxel.  Proc Natl 
Acad Sci USA 2006, 103:14513-8.
18. Szereday Z, Schally AV, Varga JL, Kanashiro CA, Hebert F, Armatis P, Groot 
K, Szepeshazi K, Halmos G, Busto R: Antagonists of growth hormone-
releasing hormone inhibit the proliferation of experimental non-small 
cell lung carcinoma.  Cancer Res 2003, 63:7913-7919.
19. Keller G, Schally AV, Groot K, Toller GL, Havt A, Köster F, Armatis P, Halmos 
G, Zarandi M, Varga JL, Engel JB: Effective treatment of experimental 
human non-Hodgkin's lymphomas with antagonists of growth 
hormone-releasing hormone.  Proc Natl Acad Sci USA 2005, 
102:10628-33.
20. Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G: 
Antagonists of growth hormone-releasing hormone and somatostatin 
analog RC-160 inhibit the growth of the OV-1063 human epithelial 
ovarian cancer cell line xenografted into nude mice.  J Clin Endocrinol 
Metab 2001, 86:2144-52.
21. Engel JB, Keller G, Schally AV, Toller GL, Groot K, Havt A, Armatis P, Zarandi 
M, Varga JL, Halmos G: Inhibition of growth of experimental human 
endometrial cancer by an antagonist of growth hormone-releasing 
hormone.  J Clin Endocrinol Metab 2005, 90:3614-3621.
22. Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K: 
Potentiation of the inhibitory effect of growth hormone-releasing 
hormone antagonists on PC-3 human prostate cancer by bombesin 
antagonists indicative of interference with both IGF and EGF 
pathways.  Prostate 2000, 44:172-80.
23. Jaffe CA, DeMott-Friberg R, Frohman LA, Barkan AL: Suppression of 
growth hormone (GH) hypersecretion due to ectopic GH-releasing 
hormone (GHRH) by a selective GHRH antagonist.  J Clin Endocrinol 
Metab 1997, 82:634-637.
24. Szepeshazi K, Schally AV, Armatis P, Groot K, Hebert F, Feil A, Varga JL, 
Halmos G: Antagonists of GHRH decrease production of GH and IGF-I in 
MXT mouse mammary cancers and inhibit tumor growth.  
Endocrinology 2001, 142:4371-8.
25. Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, 
Varga JL: Inhibition of proliferation of PC-3 human prostate cancer by 
antagonists of growth hormone-releasing hormone: lack of correlation 
with the levels of serum IGF-I and expression of tumoral IGF-II and 
vascular endothelial growth factor.  Prostate 2002, 52:173-182.
26. Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K, Czompoly T: 
Antagonists of GHRH decrease production of GH and IGF-I in MXT 
mouse mammary cancers and inhibit tumor growth.  Endocrinology 
2000, 141:2120-2128.
27. Rekasi Z, Czompoly T, Schally AV, Halmos G: Isolation and sequencing of 
cDNAs for splice variants of growth hormone releasing hormone 
receptors from human cancers.  Proc Natl Acad Sci USA 2000, 
97:10561-10566.
28. Plonowski A, Schally AV, Busto R, Krupa M, Varga JL, Halmos G: Expression 
of growth hormone-releasing hormone (GHRH) and splice variants of 
GHRH receptors in human experimental prostate cancers Peptides.  
2002, 23:1127-1133.
29. Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P, 
Szepeshazi K: The expression of growth hormonereleasing hormone 
(GHRH) and splice variants of its receptor in human 
gastroenteropancreatic carcinomas.  Proc Natl Acad Sci USA 2002, 
99:11866-11871.
30. Busto R, Schally AV, Braczkowski R, Plonowski A, Krupa M, Groot K, Armatis 
P, Varga JL: Expression of mRNA for growth hormone-releasing 
hormone and splice variants of GHRH receptors in human malignant 
bone tumors.  Regul Pept 2002, 108:47-53.
31. Garcia-Fernandez MO, Schally AV, Varga JL, Groot K, Busto R: The 
expression of growth hormone-releasing hormone (GHRH) and its 
receptor splice variants in human breast cancer lines; the evaluation of 
signaling mechanisms in the stimulation of cell proliferation.  Breast 
Cancer Res Treat 2003, 77:15-26.
32. Kiaris H, Schally AV, Busto R, Halmos G, Artavanis-Tsakonas S, Varga JL: 
Expression of a splice variant of the receptor for GHRH in 3T3 
fibroblasts activates cell proliferation responses to GHRH analogs.  Proc 
Natl Acad Sci USA 2002, 99:196-200.
33. Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga JL, Koutselini H, 
Kalofoutis A: Ligand-dependent and -independent effects of splice 
variant 1 of growth hormonereleasinghormone receptor.  Proc Natl 
Acad Sci USA 2003, 100:9512-9517.
34. Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H: 
Stimulation of proliferation of MCF-7 breastcancer cells by a 
transfected splice variant of growth hormone releasing hormone 
receptor.  Proc Natl Acad Sci USA 2007, 104:5575-5579.
35. Seitz S, Hohla F, Schally AV, Moder A, Engel JB, Horn F, Varga J, Zarandi M, 
Ortmann O, Köster F, Buchholz S: Inhibition of estrogen receptor 
positive and negative breast cancer cell lines with a growth hormone-
releasing hormone antagonist.  Oncol Rep 2008, 20:1289-94.
36. Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL, 
Halmos G: Potentiation of mammary cancer inhibition by combination 
of antagonists of growth hormone-releasing hormone with docetaxel.  
Proc Natl Acad Sci USA 2007, 104:1943-6.
37. Barabutis N, Schally AV: Antioxidant activity of growth hormone-
releasing hormone antagonists in LNCaP human prostate cancer line.  
Proc Natl Acad Sci USA 2008, 105:20470-5.
38. Barabutis N, Schally AV: Knocking down gene expression for growth 
hormone-releasing hormone inhibits proliferation of human cancer 
cell lines.  Br J Cancer 2008, 98:1790-6.
39. Volakaki AA, Lafkas D, Kassi E, Schally AV, Papavassiliou AG, Kiaris H: 
Essential role of p21/waf1 in the mediation of the antiproliferative 
effects of GHRH antagonist JMR-132.  J Mol Endocrinol 2008, 41:389-92.Guo et al. Reproductive Biology and Endocrinology 2010, 8:54
http://www.rbej.com/content/8/1/54
Page 11 of 11
40. Csernus V, Schally AV, Groot K: Antagonistic analogs of growth hormone 
releasing hormone (GHRH) inhibit cyclic AMP production of human 
cancer cell lines in vitro.  Peptides 1999, 20:843-50.
41. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL: Suppression 
of growth of H-69 small cell lung carcinoma by antagonists of growth 
hormone releasing hormone and bombesin is associated with an 
inhibition of protein kinase C signaling.  Int J Cancer 2004, 112:570-6.
42. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL: 
Inhibition of mutant p53 expression and growth of DMS-153 small cell 
lung carcinoma by antagonists of growth hormone-releasing 
hormone and bombesin.  Proc Natl Acad Sci USA 2003, 100:15836-41.
43. Zhao L, Yano T, Osuga Y, Nakagawa S, Oishi H, Wada-Hiraike O, Tang X, 
Yano N, Kugu K, Schally AV, Taketani Y: Cellular mechanisms of growth 
inhibition of human endometrial cancer cell line by an antagonist of 
growth hormone-releasing hormone.  Int J Oncol 2008, 32:593-601.
44. Chan JK, Pham H, You XJ, Cloven NG, Burger RA, Rose GS, Van Nostrand K, 
Korc M, Disaia PJ, Fan H: Suppression of ovarian cancer cell 
tumorigenicity and evasion of Cisplatin resistance using a truncated 
epidermal growth factor receptor in a rat model.  Cancer Res 2005, 
65:3243-3248.
45. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson 
DL, Bast RC Jr: Epidermal growth factor receptor expression in normal 
ovarian epithelium and ovarian cancer. I. Correlation of receptor 
expression with prognostic factors in patients with ovarian cancer.  Am 
J Obstet Gynecol 1991, 164:669-674.
46. Hackel PO, Zwick E, Prenzel N, Ullrich A: Epidermal growth factor 
receptors: critical mediators of multiple receptor pathways.  Curr Opin 
Cell Biol 1999, 11:184-18.
47. Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, 
Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, 
Podratz KC: EGF/ErbB receptor family in ovarian cancer.  Cancer Treat Res 
2002, 107:247-258.
48. Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, Wan Y: 
Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's 
effect on cell death and migration in human ovarian cancer cells.  Int J 
Oncol 2006, 29:269-78.
49. Kanashiro CA, Schally AV, Varga JL, Hammann B, Halmos G, Zarandi M: 
Antagonists of growth hormone releasing hormone and bombesin 
inhibit the expression of EGF/HER receptor family in H-69 small cell 
lung carcinoma.  M Cancer Lett 2005, 226:123-131.
50. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL: Alterations 
of EGFR/HER, angiogenesis and apoptosis pathways after therapy with 
antagonists of growth hormone releasing hormone and bombesin in 
non-small cell lung cancer.  Int J Oncol 2007, 30:1019-28.
51. Kermer P, Klöcker N, Labes M, Bähr M: Insulin-like growth factor-I 
protects axotomized rat retinal ganglion cells from secondary death 
via PI3-K-dependent Akt phosphorylation and inhibition of caspase-3 
in vivo.  J Neurosci 2000, 20:722-728.
doi: 10.1186/1477-7827-8-54
Cite this article as: Guo et al., Antiproliferative effect of growth hormone-
releasing hormone (GHRH) antagonist on ovarian cancer cells through the 
EGFR-Akt pathway Reproductive Biology and Endocrinology 2010, 8:54